Document Detail

Sildenafil: emerging cardiovascular indications.
MedLine Citation:
PMID:  15464535     Owner:  NLM     Status:  MEDLINE    
The discovery in 1989 of sildenafil, a highly selective inhibitor of phosphodiesterase-5 (PDE-5), was the result of extensive research on chemical agents targeting PDE-5 that might potentially be useful in the treatment of coronary heart disease. Initial clinical studies on sildenafil in the early 1990s were not promising with respect to its antianginal potential. However, the incidental discovery of its antiimpotence effect led to its approval of for the treatment of erectile dysfunction. Thereafter, several reports of adverse cardiac events in patients on sildenafil raised concerns about its safety in cardiovascular disorders. Novel therapeutic indications are emerging for sildenafil with the recent discovery that PDE-5 is expressed in various other tissues such as the arterial vasculature, including pulmonary and coronary arteries, venous vasculature, skeletal muscles, platelets, and visceral and tracheobronchial muscles. In this review we briefly summarize the pharmacology of sildenafil and the current available evidence on its potential therapeutic applications in cardiovascular disorders.
Shahzad G Raja; Suneela H Nayak
Related Documents :
17051755 - Coronary revascularization in a patient with immune thrombocytopenic purpura.
17969375 - Drug eluting stents: focus on cypher sirolimus-eluting coronary stents in the treatment...
8002855 - Experience with the gianturco-roubin stent for abrupt vessel closure complicating percu...
20054765 - In-hospital and mid-term clinical outcomes after percutaneous coronary intervention wit...
18082775 - Electrocardiographic algorithms for predicting the complexity of coronary artery lesion...
19913975 - Hypocalcemia following resuscitation from cardiac arrest revisited.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Annals of thoracic surgery     Volume:  78     ISSN:  1552-6259     ISO Abbreviation:  Ann. Thorac. Surg.     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-10-06     Completed Date:  2005-06-30     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  15030100R     Medline TA:  Ann Thorac Surg     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1496-506     Citation Subset:  AIM; IM    
Department of Paediatric Cardiac Surgery, Alder Hey Children's Hospital, West Derby, Liverpool, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
3',5'-Cyclic-GMP Phosphodiesterases
Blood Platelets / drug effects
Cardiovascular Diseases / drug therapy*
Coronary Circulation / drug effects
Cyclic Nucleotide Phosphodiesterases, Type 5
Endothelium, Vascular / drug effects,  physiopathology
Hemodynamics / drug effects
Hypertension, Pulmonary / drug therapy
Middle Aged
Myocardial Contraction / drug effects
Phosphodiesterase Inhibitors / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Phosphoric Diester Hydrolases / classification,  drug effects,  physiology
Piperazines / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Pulmonary Circulation / drug effects
Stress, Physiological / physiopathology
Sympathetic Nervous System / drug effects
Vasodilator Agents / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Reg. No./Substance:
0/Phosphodiesterase Inhibitors; 0/Piperazines; 0/Purines; 0/Sulfones; 0/Vasodilator Agents; 139755-83-2/sildenafil; EC 3.1.4.-/Phosphoric Diester Hydrolases; EC',5'-Cyclic-GMP Phosphodiesterases; EC Nucleotide Phosphodiesterases, Type 5; EC protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Ross II procedure: pulmonary autograft in the mitral position.
Next Document:  The biologic rationale for the use of lasers in dentistry.